Home › Compare › APLT vs ORCC

APLT vs ORCC: Dividend Comparison 2026

APLT yields 1941.75% · ORCC yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APLT wins by $7549549081.31M in total portfolio value
10 years
APLT
APLT
● Live price
1941.75%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7549549081.34M
Annual income
$6,855,073,294,458,854.00
Full APLT calculator →
ORCC
ORCC
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full ORCC calculator →

Portfolio growth — APLT vs ORCC

📍 APLT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPLTORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APLT + ORCC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
APLT pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APLT
Annual income on $10K today (after 15% tax)
$165,048.54/yr
After 10yr DRIP, annual income (after tax)
$5,826,812,300,290,026.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, APLT beats the other by $5,826,812,300,289,262.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APLT + ORCC for your $10,000?

APLT: 50%ORCC: 50%
100% ORCC50/50100% APLT
Portfolio after 10yr
$3774774540.68M
Annual income
$3,427,536,647,229,876.50/yr
Blended yield
90.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

APLT
Analyst Ratings
5
Buy
5
Hold
1
Sell
Consensus: Buy
Price Target
$0.25
+142.7% upside vs current
Range: $0.25 — $0.25
Altman Z
-35.3
Piotroski
1/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
-68.0% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APLT buys
0
ORCC buys
0
No recent congressional trades found for APLT or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPLTORCC
Forward yield1941.75% ✓4.00%
Annual dividend / share$2.00$2.00
Payout ratio50%50%
1-year div growth0%5% ✓
5-year div CAGR0%5% ✓
Portfolio after 10y$7549549081.34M ✓$28.0K
Annual income after 10y$6,855,073,294,458,854.00 ✓$899.19
Total dividends collected$7500143229.39M ✓$6.4K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$0.25$16.00 ✓

Year-by-year: APLT vs ORCC ($10,000, DRIP)

YearAPLT PortfolioAPLT Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$204,875$194,174.76$11,120$420.00+$193.8K → APLT
2$3,937,114$3,717,897.78$12,357$458.31+$3.92M → APLT
3$70,986,064$66,773,352.36$13,721$499.76+$70.97M → APLT
4$1,201,115,737$1,125,160,648.71$15,227$544.58+$1201.10M → APLT
5$19,077,920,928$17,792,727,089.23$16,885$593.02+$19077.90M → APLT
6$284,535,588,112$264,122,212,719.20$18,713$645.34+$284535.57M → APLT
7$3,985,969,128,556$3,681,516,049,275.53$20,724$701.81+$3985969.11M → APLT
8$52,464,234,462,079$48,199,247,494,524.41$22,938$762.73+$52464234.44M → APLT
9$649,042,791,475,683$592,906,060,601,258.60$25,372$828.41+$649042791.45M → APLT
10$7,549,549,081,337,835$6,855,073,294,458,854.00$28,047$899.19+$7549549081.31M → APLT

APLT vs ORCC: Complete Analysis 2026

APLT — Stock

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Full APLT Calculator →

ORCC — BDC

ORCC is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in ORCC shares.

Full ORCC Calculator →
📬

Get this APLT vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APLT vs SCHDAPLT vs JEPIAPLT vs OAPLT vs KOAPLT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.